ArticleHealth science reports2021
Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia.
Article in Health science reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Splenectomy Impact and Outcome Among Patients With Sickle Cell Disease: A Cross-Sectional Study.Health science reports · 2026Article
- Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Prevalence and Predictors of Priapism Among Patients with Sickle Cell Disease: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Predictors and health impacts of Ramadan intermittent fasting among patients with sickle cell disease.Frontiers in medicine · 2025Article
- Prevalence and predictors of Sickle Cell Nephropathy A single-center experience.Scientific reports · 2024Article
- Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications.Journal of clinical medicine · 2024Article
- Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2024Article
- Web-Based Educational Resources for Patients with Sickle Cell Disease: Availability and Reliability.International journal of general medicine · 2024Article
- Impact of Sickle Cell Disease on Academic Performance: A Cross Sectional Study.Patient preference and adherence · 2023Article
- Sickle Cell Disease Knowledge and Reproductive Decisions: A Saudi Cross-Sectional Study.Patient preference and adherence · 2023Article
- Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia.Patient preference and adherence · 2022Article
- Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia.Health science reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimHydroxyurea (HU) plays an essential role in the complex pathophysiology alteration of sickle-cell disease (SCD), which translates clinically into the enhanced quality of life and increased survival. This research examines adult patients with SCD's attitudes and awareness toward HU, as well as underutilization consequences.
methodA cross-sectional research was performed in Saudi Arabia, and adult patients with SCD were interviewed. The survey includes patient demographics, attitudes, and knowledge of HU and clinical data. The chi-square was applied through SPSS version 23 for assessing any association with outcome variables and demographic characteristics.
resultsHU is known to 72 (67.3%) of the 107 patients. The hydroxyurea treatment was initiated in 46 patients (63%). Of these, 23 (50%) discontinue HU, with the key factors being pregnancy preparation and side effects development. For those who were unaware of HU, 13 (37.1%) were admitted to the intensive care unit because of acute chest syndrome, 29 (82.8%) required a frequent blood transfusion and 12 (34.2%) with frequent hospitalizations. However, there was no significant relationship between awareness and education level (
conclusionHU is a long-established and effective disease-modifying agent for SCD patients, but it is underutilized. The causality of underuse is bidirectional between patients and healthcare providers. It is essential to educate healthcare providers and patients with SCD about hydroxyurea role in modifying disease severity, resolving adverse events, and achieving full benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.